Novartis (NYSE:NVS) has announced a $3 billion deal to acquire SNV4818, an oral, pan-mutant–selective PI3Kα inhibitor currently in Phase 1/2 trials for breast cancer and advanced solid tumors. The therapy is designed for patients with HR-positive, HER2-negative breast cancer, a segment where roughly 40% of patients harbor PIK3CA mutations. The acquisition aligns with Novartis' broader strategy to develop precision medicines that can be combined with existing treatments to improve patient outcomes. The deal includes the acquisition of Pikavation Therapeutics, a subsidiary holding the PI3kα inhibitor portfolio, and is expected to close in the first half of 2026.